Trial Profile
The Role of Bimatoprost in Graves' Periorbitopathy
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- 11 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2024.
- 11 May 2022 Planned primary completion date changed from 1 May 2022 to 1 Jul 2024.
- 29 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.